Saxagliptin: A new dipeptidyl peptidase-4 inhibitor for type 2 diabetes

Cardiology in Review

Volumn 18, Issue 4, 2010, Pages 213-217

  Lam, Sum ^a,b   Saad, Maha ^a,c  

^a ST JOHN'S UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Diabetes; Dipeptidyl peptidase 4 enzyme inhibitors; Incretins; Saxagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; 2,4-THIAZOLIDINEDIONE; ADAMANTANE; DIPEPTIDE; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; BACKACHE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; RASH; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT REDUCTION; ADULT; AGED; ANALOGS AND DERIVATIVES; CHILD; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; FEMALE; PREGNANCY; TREATMENT OUTCOME;

ADAMANTANE; ADULT; AGED; CHILD; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PREGNANCY; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 77953998497     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181daad5f     Document Type: Review

References (19)

1. World Health Organization. Diabetes: fact sheet (no.312). November 2009. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed November 28, 2009.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62-S67.
3. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
4. Onglyza -package insert-. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
5. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157.
6. Elrick H, Stimmler L, Hlad CJ Jr, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1966;24:1076-1082.
7. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 2003;3:365-372.
8. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocr Rev. 1986;63:492-498.
9. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17:161-171.
10. Trumper A, Trumper K, Trusheim H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta cells by pleiotropic signaling. Mol Endocrinol. 2001;15:1559-1570.
11. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 2000;66:91-103.
12. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolites in vivo. J Clin Endocrinol Metab. 1995;80:952-957.
13. Mentlein R. Dipeptidyl-peptidase IV (CD 26) -role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24.
14. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26:249-262.
15. Rosenstock J, Aguilar-Salinas C, Klein E, et al. CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin. 2009;25:2401-2411.
16. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Pract. 2009;63:1395-1406.
17. Defronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32: 1649-1655.
18. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611-622.
19. Hollander P, Li J, Allen E, et al; for the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810-4819.